First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2019Cited by 590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced CancerToshio Shimizu, Amita Patnaik, Michael J. Wick et al.|Clinical Cancer Research|2012Cited by 432
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid TumorsToshio Shimizu, Anthony W. Tolcher, Patricia LoRusso et al.|Clinical Cancer Research|2014Cited by 82
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Manish R. Patel et al.|Annals of Oncology|2024Cited by 66
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J. Lakhani, Yifan Zhai, Drew Rasco et al.|Clinical Cancer Research|2023Cited by 24